LATEST NEWS   Malaysia’s economy grew by 5.2 pct in 2025, exceeding the 4.0-4.8 pct forecast range --  BNM Governor | Headline inflation is expected to remain moderate in 2026, amid the continued easing in global cost conditions - BNM Governor | For 2025, the ringgit appreciated by 10.2 per cent against the US dollar, while its NEER appreciation was at 6.3 per cent- BNM | Headline and core inflation in 2025 averaged at 1.4 pct and 2.0 pct, respectively - BNM | The ringgit appreciated by 3.9 pct against the US dollar in 4Q 2025, driven by both external and domestic factors - BNM | 

Curia Burlington Named Massachusetts Manufacturer Of The Year

KUALA LUMPUR, Oct 22 (Bernama) -- Curia Global Inc (Curia) announced its Burlington, Massachusetts, sterile drug product facility has been named “Manufacturer of the Year” by the Massachusetts Legislative Manufacturing Caucus.

The award was presented at the 10th Annual Manufacturing Awards Ceremony, held on Oct 21 at Gillette Stadium, according to Curia in a statement.

“Our employees work with patients in mind every day. This recognition highlights our commitment to quality and innovation in drug manufacturing,” said Curia Burlington General Manager and Site Head, Mari-Kate Alter.

The site is one of four in Curia’s global sterile fill-finish network, which includes operations in California, New Mexico, and the United Kingdom.

The Massachusetts Manufacturing Caucus, made up of over 70 legislators, praised Curia’s contribution to the state’s economy and health sector.

“Curia exemplifies the innovation and impact of manufacturing in the Commonwealth,” said State Representative, Jeffrey Roy.

The award underscores Curia’s role in advancing pharmaceutical manufacturing while supporting high-skill jobs and patient care across Massachusetts.

Curia is a contract research, development and manufacturing organisation (CDMO) with over 30 years of experience, an integrated network of 20 global sites and 3,200 employees partnering with biopharmaceutical customers to bring life-changing therapies to market.

-- BERNAMA